Drug Profile
MP 106
Alternative Names: MP-106Latest Information Update: 26 Nov 2015
Price :
$50
*
At a glance
- Originator Marathon Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 Nov 2015 Discontinued - Phase-III for Cancer in USA (unspecified route)